Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00821496
Recruitment Status : Completed
First Posted : January 13, 2009
Last Update Posted : December 2, 2009
Sponsor:
Information provided by:
VIVUS, Inc.

Brief Summary:
This study is desgigned to look at the effect of multiple dosing administration of VI-0521 on Oral Contraceptive medication.

Condition or disease Intervention/treatment Phase
Healthy Drug: ethinyl estradiol, norethindrone, VI-0521 Phase 1

Detailed Description:
This study is designed to determine if multiple oral doses of VI-0521 would alter the pharmacokinetics of an oral contraceptive in healthy female subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open Label, Fixed Sequence, Single-Center Study to Evaluate the Effect of Multiple Dose Administration of VI-0521 on the Pharmacokinetics of a Single Dose of Oral Contraceptive in Healthy Female Subjects
Study Start Date : January 2009
Actual Primary Completion Date : March 2009
Actual Study Completion Date : April 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Oral Contraceptive Drug: ethinyl estradiol, norethindrone, VI-0521
Oral contraceptive
Other Name: VI-0521, Ortho-Novum 1/35-28




Primary Outcome Measures :
  1. PK of the Oral contraceptive agent [ Time Frame: 31 days ]

Secondary Outcome Measures :
  1. saftey and tolerability of multiple dose adminstration of VI-0521 in healthy female subjects [ Time Frame: 31 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 64 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Females, 19 - 64 years of age (inclusive), who are non-pregnant, not planning pregnancy and non-breast-feeding.
  2. If females of child-bearing potential, be using adequate contraception, defined as double barrier methods, single barrier plus tubal ligation.
  3. A body weight of at least 50 kg and a body mass index (BMI) between 27 and 35 kg/m2, inclusive.
  4. Medically healthy, with clinically insignificant screening results.
  5. Subjects are able to communicate with the investigator, and to understand and comply with all requirements of study participation.
  6. Voluntarily consent to participate in the study.

Exclusion Criteria:

  1. A history or presence of significant cardiovascular, neurological, hematological, psychiatric, hepatic, gastrointestinal, pulmonary, endocrine, immunologic or renal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs or place the subjects at increased risk as determined by the investigator.
  2. Any clinically significant laboratory abnormalities as judged by the investigator.
  3. Any history of glaucoma, increased intraocular pressure, or medications to treat increased intraocular pressure.
  4. Presence of cholelithiasis or cholecystitis within the last 6 months that has not been surgically treated with cholecystectomy.
  5. Any history of a cardiovascular or cerebrovascular event.
  6. Systolic blood pressure > 150 mm Hg or diastolic blood pressure > 95 mm Hg at screening or at check-in on Day -1.
  7. Positive urine drug test, serum cotinine test, pregnancy test and/or positive urine alcohol test at screening or check in Day -1.
  8. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV) at screening.
  9. Any history or presence of alcoholism or drug or substance abuse as defined by the investigator.
  10. Any active malignancy except basal cell carcinoma.
  11. A history of breast cancer.
  12. Any history of bipolar disorder or psychosis, history of psychiatric hospitalization, greater than one lifetime episode of major depression.
  13. A history of intolerance to oral contraceptives.
  14. A history of hypersensitivity or idiosyncratic reaction to the active drugs, compounds related to the study drugs or to any excipients present in the VI-0521 capsule.
  15. Use of any prescription or over-the-counter (OTC) medication, including herbal products, within the 14 days prior to Day -1. Up to 2 g per day of acetaminophen is allowed at the discretion of the Investigator.
  16. Use of any drug known to have a significance in inhibiting or inducing liver enzymes involved in drug metabolism [CYP P450]) within 30 days prior to Day -1.
  17. Blood donation or significant blood loss within 56 days prior to Day -1.
  18. Plasma donation within 7 days prior to Day -1.
  19. Any use of tobacco or nicotine products within 3 months prior to Day -1.
  20. Any history of celiac diseases, food allergies, and those on vegetarian or other diets incompatible with study objectives.
  21. Any subject who received an investigational drug within 30 days or six half-lives, whichever is longer, prior to dosing in this study.
  22. Clinical judgment by the investigator that the subject should not participate in the study.
  23. Involvement in the planning and conduct of the study.
  24. Any subject who has participated in a previous clinical trial with VI-0521.
  25. Subjects with any condition possibly affecting drug absorption.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00821496


Locations
Layout table for location information
United States, Arizona
MDS Pharma Services
Phoenix, Arizona, United States, 85283
Sponsors and Collaborators
VIVUS, Inc.
Investigators
Layout table for investigator information
Study Director: Shiyin Yee VIVUS, Inc.
Principal Investigator: Scott Sharples, M.D. MDS Pharma Services
Layout table for additonal information
Responsible Party: Wesley Day, VP Clinical, Vivus, Inc.
ClinicalTrials.gov Identifier: NCT00821496    
Other Study ID Numbers: OB-108
First Posted: January 13, 2009    Key Record Dates
Last Update Posted: December 2, 2009
Last Verified: November 2009
Keywords provided by VIVUS, Inc.:
Multiple dose administration
Oral Contraceptives
Additional relevant MeSH terms:
Layout table for MeSH terms
Norethindrone
Norethindrone Acetate
Norinyl
Estradiol
Ethinyl Estradiol
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Female
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptives, Oral, Combined